The fourth hurdle as controlling instrument for expenditure on medication? W. KulpW. GreinerJ.-M. von der Schulenburg Editorial Pages: 1 - 5
The assessment of the economic return from controlled clinical trials D. CoyleE. GrunfeldG. Wells Original Papers Pages: 6 - 11
A pharmacoeconomic evaluation of escitalopram, a new selective serotonin reuptake inhibitor C. FrançoisM. ToumiK. Hansen Original Papers Pages: 12 - 19
What criteria for pharmaceuticals reimbursement? C. Le PenG. PriolH. Lilliu Original Papers Pages: 30 - 36
The cost-effectiveness of early cabergoline treatment compared to levodopa in Sweden P. LindgrenB. JönssonJ. DuChane Original Papers Pages: 37 - 42
Implementing standardized cost categories within economic evaluations in musculoskeletal diseases T. MittendorfS. MerkesdalJ. Ruof Original Papers Pages: 43 - 49
Cost-utility of interferon β1b in the treatment of patients with active relapsing-remitting or secondary progressive multiple sclerosis G. KobeltL. JönssonS. Fredrikson Original Papers Pages: 50 - 59
Pricing and reimbursement of drugs in Denmark K. Møller Pedersen Pricing and Reimbursement Systems in Europe Pages: 60 - 65